STOCK TITAN

Reviva Pharmaceuticals Holdings Inc. - RVPH STOCK NEWS

Welcome to our dedicated news page for Reviva Pharmaceuticals Holdings (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceuticals Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Reviva Pharmaceuticals Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Reviva Pharmaceuticals Holdings's position in the market.

Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that its CEO will present at the 2024 BIO CEO & Investor Conference in New York, focusing on therapies for CNS, inflammatory, and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will host a virtual event on February 15, 2024, featuring key opinion leaders discussing the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia. The event will focus on the positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
conferences clinical trial
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced the participation of its CEO in a fireside chat at the Lytham Partners 2024 Investor Select Conference. The company will also host virtual one-on-one meetings with investors. The webcasted fireside chat will take place on February 1, 2024, and will be available for replay. Management will be participating in virtual one-on-one meetings throughout the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announces CEO presentation at Webull LIVE! Virtual Healthcare Investment Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, a late-stage pharmaceutical company (NASDAQ: RVPH), provided program updates on its late-stage brilaroxazine clinical program in schizophrenia, including positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data. The company also announced the initiation of registrational Phase 3 RECOVER-2 trial expected Q1 2024 and topline data from 1-year OLE trial expected Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that Dr. Laxminarayan Bhat, Founder, President, and CEO, will participate in a live 'CEO Chat' session at the Life Sciences Investor Forum on December 14th, 2023. The forum will focus on the company's late-stage therapies for CNS, inflammatory, and cardiometabolic diseases, offering investors an opportunity to engage with Dr. Bhat and John Vandermosten, Senior Biotechnology Analyst with Zacks Small-Cap Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
conferences
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced participation in The Benchmark Company’s Discovery One-on-One Investor Conference. Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO, will attend the event in New York, NY on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced the closure of a registered direct offering, raising approximately $30,000,000 in gross proceeds. The offering involved the sale and issuance of 5,853,660 shares of common stock and warrants to purchase up to 5,853,660 shares at a combined offering price of $5.125 per share. The company plans to utilize the net proceeds for research and development activities, including the registrational Phase 3 RECOVER-2 trial, and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
offering
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Announces Registered Direct Offering of Common Stock and Warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
offering
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported positive results from its global Phase 3 RECOVER trial for brilaroxazine in treating schizophrenia. The trial met primary and secondary endpoints, showing statistically significant and clinically meaningful symptom reductions at week 4 with 50 mg of brilaroxazine compared to placebo. The company also announced financial results for the third quarter and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.93%
Tags
earnings
Reviva Pharmaceuticals Holdings Inc.

Nasdaq:RVPH

RVPH Rankings

RVPH Stock Data

121.45M
17.14M
17.77%
18.74%
3.01%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Cupertino

About RVPH

reviva pharmaceuticals is a pharmaceuticals company located in 5941 optical ct, san jose, california, united states.